EVOLVE Short DAPT
JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Session evaluation and key learnings
Shortened dual antiplatelet therapy in contemporary percutaneous coronary intervention era
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Can We Define High-risk DAPT Patients in USA Practice? - ppt download
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
Two further studies support three-month DAPT following PCI
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Primary Results of the EVOLVE Short DAPT Study | Circulation: Cardiovascular Interventions
BostonSci Cardiology on X: "See how SYNERGY™ BP Stent performed 12-months post-DAPT discontinuation in the EVOLVE Short #DAPT Trial: https://t.co/fQIpaJOGOC Safety Info: https://t.co/aA0ofN4r9t https://t.co/lrWq5mVKBT" / X
Studying DAPT – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis) - ScienceDirect
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review | Published in Journal of Brown Hospital Medicine
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect
Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science | tctmd.com
